Atlas Trials

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Clinical trial NCT01735968 · COMPLETED

Trial details

NCT number
NCT01735968
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
3rd Line GIST
Start date
2013-02-27
Primary completion
2018-10-19
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.